Palliative care 2016

Phase II or retrospec+ve cohorts

Author; year

Design

Pts

Dose/frx

m-­‐FU

Locol control (%)

Survival 1,2 years 1, 2 years (%)

3x10-­‐12.5 Gy 1x26 Gy

Wulf 2004

Dose esc.

41

9 mts

80

85, 33

83 (>26 Gy and <10cc)

Hof 2007

Phase I/II

61

1x12-­‐30 Gy

14 mts

78, 65

Rusthoven 2009 Phase I/II

38

3x16-­‐20 Gy

15 mts

96

65, 39

Zhang 2011

Retrospect

71

3-­‐5x12 Gy 1x26 Gy, 3x15 Gy, 4x9 Gy

25 mts

97, 89

79, 41 (3 yr)

Ricardi 2012

Retrospect

61

20 mts

89

79, 67

Comito 2014 Lung mets: Local control rates 80-­‐96% Phase II 40 24 80 80, 65

4x12 – 3x25 Gy

33 (incl brain)

DeVin 2014

Retrospect

56

10x4-­‐5 Gy

12 mts

55 (2 yr)

12x5 Gy 1x44 Gy

Takahachi 2014 Carbon ions Feasibility

34

24 mts

85

90, 65

Fode 2015

Retrospect Retrospect Mul+-­‐inst

92

3x15-­‐22.5 Gy

29

LR: 13

80, 58

Guckenberger/ DEGRO (abstract)

53 (2 yr) 24 (5 yr)

715

NA

NA

NA